News
Proteasome Inhibition May Increase Alectinib Efficacy in ALK/TP53-Mutated NSCLC
Investigators studied genetic alterations related to ALK-TKI resistance in NSCLC and explored strategies to overcome resistance in preclinical models.
Your search for non small cell lung cancer returned 27 results
News
Sotorasib Under Review for KRAS G12C-Mutated Locally Advanced or Metastatic NSCLC
The Food and Drug Administration has placed sotorasib under priority review for patients with KRAS G12C-mutated locally advanced or metastatic NSCLC.
ESMO 2021, News
Adding Bevacizumab to Erlotinib Prolongs PFS in Non-Squamous Non-Small Cell Lung Cancer
There was no improvement in overall survival with bevacizumab.
ESMO 2021, News
Sugemalimab Deemed Effective as Consolidation for Stage III Non-Small Cell Lung Cancer
Sugemalimab improved progression-free survival whether patients received sequential or concurrent chemoradiotherapy.
ESMO 2021, News
Brigatinib Continues to Best Crizotinib in ALK+ Non-Small Cell Lung Cancer
There was an improvement in progression-free survival despite crossover.
Drugs in the Pipeline
Poziotinib Under Review for Previously Treated HER2 Exon 20 Insertion Mutation Positive NSCLC
A PDUFA target date of November 24, 2022 has been set for the application.
Drugs in the Pipeline
Adagrasib Under Review for Previously Treated KRAS G12C-Mutated NSCLC
The application is supported by data from the registration-enabling cohort of the phase 2 KRYSTAL-1 study evaluating adagrasib in adults with NSCLC harboring the KRASG12C mutation following prior systemic therapy.
News
Combined Modalities Improve Survival in Stage III Inoperable NSCLC
This study tested the efficacy of singular and combined treatment modalities on survival in patients with inoperable, locally advanced non-small cell lung cancer (≥70 years).
Drugs in the Pipeline
Atezolizumab Gets Priority Review as Adjuvant Treatment for Early NSCLC
The sBLA is supported by data from the IMpower010 study that compared atezolizumab with best supportive care in 1005 adults with Stage IB-IIIA NSCLC after resection and adjuvant chemotherapy.
Drugs in the Pipeline
Patritumab Deruxtecan Gets Breakthrough Tx Status for Metastatic EGFR-Mutated NSCLC
Patritumab deruxtecan consists of a fully human anti-HER3 IgG1 monoclonal antibody attached to a topoisomerase I inhibitor payload (an exatecan derivative, DXd) via a stable tetrapeptide-based cleavable linker.
